Cart
sales@molnova.com
Taprizosin
CAS No. 210538-44-6
Taprizosin( —— )
Catalog No. M34440 CAS No. 210538-44-6
Taprizosin（UK-338003） is a selective and orally active α1-adrenoceptor antagonist for vasodilatation in the treatment of benign prostatic hyperplasia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 851 | In Stock |
|
| 10MG | 1169 | In Stock |
|
| 25MG | 1786 | In Stock |
|
| 50MG | 2399 | In Stock |
|
| 100MG | 3162 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTaprizosin
-
NoteResearch use only, not for human use.
-
Brief DescriptionTaprizosin（UK-338003） is a selective and orally active α1-adrenoceptor antagonist for vasodilatation in the treatment of benign prostatic hyperplasia.
-
DescriptionTaprizosin（UK-338003） is a selective and orally active α1-adrenoceptor antagonist for vasodilatation in the treatment of benign prostatic hyperplasia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAdrenergic Receptor
-
RecptorAdrenergic Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number210538-44-6
-
Formula Weight506.58
-
Molecular FormulaC25H26N6O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNC=1C=2C(=C(OC)C(OC)=CC2N=C(N1)N3CC=4C(CC3)=C(NS(C)(=O)=O)C=CC4)C5=CC=CC=N5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
CGP 20712 A
CGP 20712 A (CGP 20712 mesylate) is a selective and potent β1-adrenergic receptor antagonist (IC50: 0.7 nM) with antihypertensive activity, capable of reversing RKT-induced gastric relaxation.
-
Atipamezole hydrochl...
Antipamezole (MPV-1248) is a potent, specific α2-adrenoceptor antagonist with Ki of 1.6 nM.
-
Tamsolusin Hydrochlo...
Tamsolusin Hydrochloride (YM 12617) is a highly selective alpha-1A adrenergic receptor antagonist used in the treatment of benign prostatic hypertrophy.
